EA035877B1 - Оксим-замещенные 5-бром-индирубины - Google Patents

Оксим-замещенные 5-бром-индирубины Download PDF

Info

Publication number
EA035877B1
EA035877B1 EA201591709A EA201591709A EA035877B1 EA 035877 B1 EA035877 B1 EA 035877B1 EA 201591709 A EA201591709 A EA 201591709A EA 201591709 A EA201591709 A EA 201591709A EA 035877 B1 EA035877 B1 EA 035877B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
carcinoma
compound according
compound
pharmaceutically acceptable
Prior art date
Application number
EA201591709A
Other languages
English (en)
Russian (ru)
Other versions
EA201591709A1 (ru
Inventor
Ричард Джоув
Сангкил Нам
Дэвид Хорн
Цзюнь Се
Алексиос Леандрос Скалтсоунис
Марина Критсанида
Николас Габорьо-Колар
Original Assignee
Сити Оф Хоуп
Нэшнл Энд Каподистриан Юниверсити Оф Атенс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сити Оф Хоуп, Нэшнл Энд Каподистриан Юниверсити Оф Атенс filed Critical Сити Оф Хоуп
Publication of EA201591709A1 publication Critical patent/EA201591709A1/ru
Publication of EA035877B1 publication Critical patent/EA035877B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201591709A 2013-03-14 2014-03-14 Оксим-замещенные 5-бром-индирубины EA035877B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783290P 2013-03-14 2013-03-14
PCT/US2014/028730 WO2014153023A1 (en) 2013-03-14 2014-03-14 5-bromo-indirubins

Publications (2)

Publication Number Publication Date
EA201591709A1 EA201591709A1 (ru) 2016-03-31
EA035877B1 true EA035877B1 (ru) 2020-08-25

Family

ID=51581389

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591709A EA035877B1 (ru) 2013-03-14 2014-03-14 Оксим-замещенные 5-бром-индирубины

Country Status (12)

Country Link
US (4) US20160068517A1 (enExample)
EP (1) EP2970310B1 (enExample)
JP (1) JP6422936B2 (enExample)
KR (1) KR102275112B1 (enExample)
CN (1) CN105283456B (enExample)
AU (1) AU2014236370C1 (enExample)
BR (1) BR112015023383A2 (enExample)
CA (1) CA2902914A1 (enExample)
EA (1) EA035877B1 (enExample)
IL (1) IL240916A0 (enExample)
MX (1) MX2015013021A (enExample)
WO (1) WO2014153023A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015013021A (es) 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
AU2018358582B2 (en) * 2017-10-31 2021-06-10 Pelemed Co., Ltd. Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
WO2007099402A2 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2801216A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
ATE529402T1 (de) * 2008-08-01 2011-11-15 Centre Nat Rech Scient 3',6-substituierte indirubine und ihre biologischen anwendungen
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
EP2733140A4 (en) 2011-07-15 2014-11-26 Univ Nihon INDIRUBINE DERIVATIVE WITH HIGHLY SELF-ACTIVE CYTOTOXICITY FOR POOR TUMORS
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
MX2015013021A (es) * 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
WO2007099402A2 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anne Beauchard et al. 'Synthesis of novel 5-substituted indirubins as protein kinase inhibitors', Bioorganic & Medicinal Chemistry, 2006, Vol. 14, No. 18, pp. 6434-6443 See Compound 38,40 *
Chemistry & Biodiversity, Vol. 9, No. 10, pp. 2175-2185 Chemistry & Biodiversity, Vol. 9, No. 10, pp. 2175-2185 See Compound 1b, 3b *
GRYAZNOV SERGEI M: "Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.", CHEMISTRY & BIODIVERSITY, HELVETICA CHIMICA ACTA, ZUERICH, CH, vol. 7, no. 3, 1 March 2010 (2010-03-01), CH, pages 477 - 493, XP002759310, ISSN: 1612-1872, DOI: 10.1002/cbdv.200900187 *

Also Published As

Publication number Publication date
US20180170915A1 (en) 2018-06-21
CN105283456B (zh) 2018-12-18
IL240916A0 (en) 2015-10-29
US11306072B2 (en) 2022-04-19
EP2970310A1 (en) 2016-01-20
MX2015013021A (es) 2016-07-14
CA2902914A1 (en) 2014-09-25
BR112015023383A2 (pt) 2017-07-18
KR20160006669A (ko) 2016-01-19
JP6422936B2 (ja) 2018-11-14
US20220274964A1 (en) 2022-09-01
HK1220197A1 (zh) 2017-04-28
KR102275112B1 (ko) 2021-07-08
WO2014153023A1 (en) 2014-09-25
EP2970310A4 (en) 2016-09-07
JP2016514160A (ja) 2016-05-19
AU2014236370C1 (en) 2019-01-17
US20200283421A1 (en) 2020-09-10
US20160068517A1 (en) 2016-03-10
EA201591709A1 (ru) 2016-03-31
EP2970310B1 (en) 2020-11-11
AU2014236370A1 (en) 2015-09-17
CN105283456A (zh) 2016-01-27
AU2014236370B2 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
US11964941B2 (en) 5-Bromo-indirubins
US11730736B2 (en) Anticancer agents
US20220274964A1 (en) 5-bromo-indirubins
US9862693B2 (en) Compounds and methods of treating cancer
WO2022246597A1 (en) Imidazopyridine derivatives as sting agonists
US20210323913A1 (en) Sigma receptor binders
US20190016714A1 (en) Deoxycytidine kinase binding compounds
JP2024538131A (ja) 膀胱癌処置のための低酸素誘導因子２（アルファ）阻害剤
US20230135758A1 (en) Elongation factor 1-alpha inhibitors and uses thereof
US20230127630A1 (en) Igf2bp2 inhibitors and uses thereof
US20220274929A1 (en) Thiosemicarbazone compounds and uses thereof
US11213510B2 (en) Thioindirubins
US20230203003A1 (en) Notch Inhibitors and Uses Thereof
WO2021237111A1 (en) Notch inhibitors and uses thereof
HK1220197B (en) 5-bromo-indirubins

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU